Caplin Point Laboratories has received Colombia`s INVIMA approval for its Softgel Capsules division at Puducherry. The site inspection of Unit-1 was completed on 03 May and found compliant as per INVlMA`s norms of Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP).Powered by Capital Market - Live News

Caplin Steriles, a Subsidiary Company of Caplin Point Laboratories has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Ofloxacin Ophthalmic Solution USP 0.3% (eye drops), a generic therapeutic equivalent version of (RLD), OCUFLOX Ophthalmic Solution of Allergan Inc.Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers. According to IQVIATM (IMS Health), Ofloxacin Ophthalmic Solution USP 0.3% had US sales of approximately $52 million for the 12-month period ending December 2023.Powered by Capital Market - Live News

Net profit of Caplin Point Laboratories rose 20.23% to Rs 117.20 crore in the quarter ended December 2023 as against Rs 97.48 crore during the previous quarter ended December 2022. Sales rose 17.05% to Rs 435.50 crore in the quarter ended December 2023 as against Rs 372.07 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales435.50372.07 17 OPM %32.6729.40 - PBDT159.31123.17 29 PBT145.41111.74 30 NP117.2097.48 20 Powered by Capital Market - Live News

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 9 February 2024.Powered by Capital Market - Live News

Caplin Group of Companies announced the signing of a Memorandum of Understanding (MoU) with the Tamil Nadu Government during the Tamil Nadu Global Investors Meet, 2024. This MoU outlines Caplin Group`s commitment to invest Rs 700 crore over a period of 5 years in diverse projects. This investment will be made by Caplin Point Laboratories and its subsidiaries - Caplin Steriles and Caplin One Labs.The MoU specifies that the government will provide necessary infrastructure and regulatory assistance as per applicable laws. This will also enable the availing of standard incentives, subject to eligibility. The investments, spanning Oncology, Active Pharmaceutical Ingredients and R&D facilities, are projected to generate 1,500 employment opportunities (1,000 direct and 500 indirect).Powered by Capital Market - Live News